Gutierrez M, Moreno V, Heinhuis KM, Olszanski AJ, Spreafico A, Ong M, Chu QS, Carvajal RD, Trigo J, Ochoa de Olza M, Provencio M, De Vos F, de Braud F, Leong S, Lathers D, Wang R, Ravindran P, Feng Y, Aanur P, Melero I
This phase 1/2a study (NCT02737475) evaluated the safety and activity of BMS-986178, a fully human OX40 agonist immunoglobulin G1 monoclonal antibody, ± nivolumab and/or ipilimumab in patients with advanced solid tumors.
